Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05 2023 - 08:00AM
GlobeNewswire Inc.
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology
company focused on developing and launching the first curative
targeted cell therapies for patients with autoimmune diseases,
today announced that Steven Nichtberger, M.D., Chief Executive
Officer, will present at the 41st Annual J.P. Morgan Conference
being held in San Francisco, CA on Thursday, January 12th at 7:30
a.m. PT (10:30 a.m. ET).
A live webcast of the presentation will be available on the News
and Events section of the Company’s website at
www.cabalettabio.com. Replays of the presentation will be available
on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage
biotechnology company focused on the discovery and development of
engineered T cell therapies that have the potential to provide a
deep and durable, perhaps curative, treatment for patients with
autoimmune diseases. The CABA™ platform encompasses two strategies:
the CARTA (chimeric antigen receptor T cells for autoimmunity)
strategy, with CABA-201, a 4-1BB-containing CD19-CAR T, as the lead
product candidate, and the CAART (chimeric autoantibody receptor T
cells) strategy, with multiple clinical-stage candidates, including
DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK
myasthenia gravis. The expanding CABA™ platform may offer
potentially curative therapies for patients with a broad range of
autoimmune diseases. Cabaletta Bio’s headquarters are located in
Philadelphia, PA.
Contacts
Anup MardaChief Financial Officerinvestors@cabalettabio.com
Sarah McCabeStern Investor Relations,
Inc.212-362-1200sarah.mccabe@sternir.com
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From May 2023 to Jun 2023
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Jun 2022 to Jun 2023